Drug intelligence / Profile preview

daclizumab + basiliximab

Development stage: Unknown
Lead developer: Biogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Daclizumab and basiliximab are monoclonal antibodies that function as interleukin-2 receptor antagonists. They specifically bind to and block the interleukin-2 receptor alpha-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. This inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. Both antibodies are used for prophylaxis of acute organ rejection in patients receiving renal transplants.

Targets

IL2RA (Interleukin-2 receptor alpha subunit)

Beyond the preview

Go deeper on daclizumab + basiliximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on daclizumab + basiliximab.

Explore the full profile